Page 49 - 22-0424
P. 49

The International Journal of the Royal Society of Thailand
                                                                                         Volume XI - 2019



                treatment modalities for individual patients. However, the cost and access to
                these treatment is still an important hurdle. This issue hope to be resolved in the
                near future and precision medicine will become the standard treatment for other

                neurological disorders.


                References

                Adams D, Gonzalez-Duarte A, O’Riordan W, Yang C, Ueda M, Kristen A, et al.
                        Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.
                        N Engl J Med. 2018;379:11–21. doi:10.1056/NEJMoa1716153.
                American Headache Society. The American Headache Society Position Statement
                        on integrating new migraine treatments into clinical practice. Headache.
                        2019; 59 1–18. doi:10.1111/head.13456.

                Baud MO and Rao VR. Gauging seizure risk. Neurology. 2018;91:967–973.
                        doi:10.1212/WNL.0000000000006548.

                Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck P, Wang A et al.
                        Inotersen treatment for patients with hereditary transthyretin amyloidosis.
                        N Engl J Med. 2018;379:22–31. doi:10.1056/NEJMoa1716793.

                Birnkrant D, Bushby K, Bann C, Apkon S, Blackwell A, Brumbaugh D, et al.
                        Diagnosis and management of Duchenne muscular dystrophy, part 1:
                        diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal
                        and nutritional management. Lancet Neurol. 2018;17:251–267. doi:10.1016/
                        S1474-4422(18)30024-3.

                Birnkrant DJ, Bushby K, Bann CM, Alman BA , Apkon SD, Blackwell A, et al.
                        Diagnosis and management of Duchenne muscular dystrophy, part 2:
                        respiratory, cardiac, bone health, and orthopaedic management. Lancet
                        Neurol. 2018;17:347–361. doi:10.1016/S1474-4422(18)30025-5.

                Brooks M. FDA OKs first gene therapy for spinal muscular atrophy [Internet].
                        New York: Medscape; 2019 May 24 [cited 2021 Mar 10]. Available from:
                        https://www.medscape.com/viewarticle/913505

                Draper S. Wearable technology can predict or even prevent epileptic seizures
                        [Internet]. 2019 May 23 [cited 2019 August 2]. Available from: https://www.
                        wearable-technologies.com/2019/05/wearable-technology-can-predict-
                        or-even-prevent-epileptic-seizures/.




                                                                                                    43
                     Kongkiat Kulkantrakorn



                                                                                                  11/7/2565 BE   13:27
       _22-0424(037-046)5.indd   43
       _22-0424(037-046)5.indd   43                                                               11/7/2565 BE   13:27
   44   45   46   47   48   49   50   51   52   53   54